Abstract
1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) has recently proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. Combinations of HEPT and recombinant alpha interferon (IFN-alpha) synergistically inhibit the replication of HIV-1 in MT-4 cells at non-toxic concentrations. Synergistic inhibition of HIV-1 replication has also been observed in peripheral blood lymphocytes. These results indicate that the combination of HEPT with IFN-alpha should be further pursued in the treatment of retrovirus infections [i.e. acquired immune deficiency syndrome (AIDS)].
MeSH terms
-
Acquired Immunodeficiency Syndrome / drug therapy
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / microbiology
-
Cells, Cultured
-
Cytopathogenic Effect, Viral
-
Drug Synergism
-
Drug Therapy, Combination
-
HIV-1 / drug effects*
-
HIV-1 / growth & development
-
HIV-1 / physiology
-
Humans
-
Interferon Type I / pharmacology*
-
Interferon Type I / therapeutic use
-
Recombinant Proteins
-
Thymine / analogs & derivatives*
-
Thymine / pharmacology
-
Thymine / therapeutic use
-
Virus Replication / drug effects*
Substances
-
Interferon Type I
-
Recombinant Proteins
-
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
-
Thymine